IL17A and myeloid sarcoma: It’s worth noting that the circulating level of TNF-α and IL-17 was significantly increased in MS-affected patients relative to HCs [49], suggesting the absence of endogenous α-DIPA may be a causal factor resulting in activation of TNF-α and IL-17 in patients with MS.